文献速递泌尿男性生殖肿瘤

纳武利尤单抗联合多西他赛对比安慰剂联合多西他赛治疗ARPI经治且化疗初治的mCRPC:CheckMate 7DX双盲随机III期试验

Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

CheckMate 7DX是一项双盲随机III期试验,纳入1030例ARPI经治且化疗初治的转移性去势抵抗性前列腺癌(mCRPC)患者,比较纳武利尤单抗联合多西他赛与安慰剂联合多西他赛的疗效与安全性。联合纳武利尤单抗未改善rPFS或OS,且3-4级治疗相关不良事件发生率更高。

要点

  • 纳武利尤单抗联合多西他赛未改善ARPI经治化疗初治mCRPC的rPFS或OS。
  • 联合组3-4级治疗相关不良事件发生率为44%,高于对照组的37%。
  • 结果不支持在未筛选的ARPI经治化疗初治mCRPC人群中联合抗PD-1与多西他赛。

核心结论

  • 在ARPI经治且化疗初治的mCRPC患者中,纳武利尤单抗联合多西他赛对比安慰剂联合多西他赛未改善影像学无进展生存期或总生存期。
  • 这些发现不支持在未筛选的ARPI经治化疗初治mCRPC人群中联合使用抗PD-1免疫检查点抑制剂与多西他赛。

研究设计与样本

  • CheckMate 7DX为双盲、随机、III期试验,在27个国家291家医院和癌症中心入组成人ARPI经治且化疗初治的mCRPC患者。
  • 患者按1:1随机分配至纳武利尤单抗(360 mg)或多西他赛(75 mg/m2)静脉每3周最多10次,随后纳武利尤单抗(480 mg)或等效安慰剂每4周。
  • 共筛查1414例,随机分配1030例至纳武利尤单抗联合多西他赛组(n=514)或安慰剂联合多西他赛组(n=516)。
  • 主要终点为盲态独立中心评审的影像学无进展生存期和总生存期,在所有随机化患者中评估。
  • 安全性在至少接受一剂研究药物的所有患者中评估。

主要发现

  • 3-4级治疗相关不良事件在纳武利尤单抗联合多西他赛组510例中发生223例(44%),安慰剂联合多西他赛组510例中发生187例(37%)。
  • 两组最常见的3-4级事件为中性粒细胞减少(纳武利尤单抗联合多西他赛组37例[7%],安慰剂联合多西他赛组50例[10%])和中性粒细胞计数降低(分别为41例[8%]和39例[8%])。
  • 任何级别治疗相关严重不良事件在纳武利尤单抗联合多西他赛组发生107例(21%),安慰剂联合多西他赛组发生77例(15%)。

关键数值与推荐

  • 入组患者为组织学确诊的ARPI经治且化疗初治的mCRPC成人(≥18岁),筛查前6个月内有记录疾病进展,ECOG体能状态评分0或1。
  • 随机化按既往ARPI治疗和内脏疾病分层,使用交互式响应技术、区组大小为6的置换区组。
  • 患者、研究者和申办方对个体治疗分配设盲。

临床怎么用

  • 对于ARPI经治且化疗初治的mCRPC患者,不应在未筛选人群中常规联合抗PD-1免疫检查点抑制剂与多西他赛。
  • 临床决策应继续基于已确立的标准治疗,联合方案需等待生物标志物筛选等进一步研究。

局限性

  • 研究未报告基于生物标志物筛选的亚组分析结果,无法确定潜在获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen receptor pathway inhibitors (ARPIs) and docetaxel are established standards of care for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). We aimed to assess the efficacy and safety of adding nivolumab to docetaxel versus docetaxel alone in ARPI-pretreated, chemotherapy-naive mCRPC. METHODS: CheckMate 7DX was a double-blind, randomised, phase 3 trial that enrolled adult patients (aged ≥18 years) with histologically confirmed, ARPI-pretreated, and chemotherapy-naive mCRPC at 291 hospitals and cancer centres across 27 countries. Patients had documented progression within 6 months of screening and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to nivolumab (360 mg), or equivalent placebo, and docetaxel (75 mg/m2) intravenously every 3 weeks for up to ten doses, followed by nivolumab (480 mg) or equivalent placebo every 4 weeks. Randomisation, stratified by previous ARPI therapy and visceral disease, was done using interactive response technology in permuted blocks with a block size of six. Patients, investigators, and the trial sponsor were masked to individual patient treatment assignment. The primary endpoints were radiographic progression-free survival by blinded independent central review and overall survival, assessed in all randomly assigned patients. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04100018, and is completed. FINDINGS: Between March 11, 2020, and Aug 2, 2022, 1414 patients were screened for eligibility, 1030 of whom were randomly assigned to nivolumab plus docetaxel (n=514) or placebo plus docetaxel (n=516). All participants were male, median age was 70 years (range 34-91), 662 (64%) were White, 240 (23%) were Asian, and 35 (3%) were Black or African American. With a median follow-up of 17·2 months (IQR 13·2-22·0), median radiographic progression-free survival was 9·4 months (95% CI 8·5-10·3) in the nivolumab plus docetaxel group versus 8·7 months (95% CI 8·4-10·0) in the placebo plus docetaxel group (hazard ratio [HR] 0·96 [99% CI 0·77-1·19]; p=0·59) and median overall survival was 18·7 months (95% CI 17·0-21·0) versus 18·9 months (95% CI 17·3-22·0, HR 1·09 [99·41% CI 0·84-1·43]; p=0·36). Grade 3-4 treatment-related adverse events occurred in 223 (44%) of 510 patients in the nivolumab plus docetaxel group and 187 (37%) of 510 in the placebo plus docetaxel group. The most common grade 3-4 events in both treatment groups were neutropenia (37 [7%] in the nivolumab plus docetaxel group and 50 [10%] in the placebo plus docetaxel group) and decreased neutrophil count (41 [8%] and 39 [8%]). Any-grade treatment-related serious adverse events occurred in 107 (21%) patients in the nivolumab plus docetaxel group and 77 (15%) in the placebo plus docetaxel group. 12 deaths were attributed to nivolumab plus docetaxel (three due to sepsis; one each due to Guillain-Barré syndrome, diverticulitis, myocarditis, liver injury, peritonitis, pneumonitis, pneumonia, and diarrhoea; and one due to unknown causes) and one was attributed to placebo plus docetaxel (due to pneumocystis). INTERPRETATION: Nivolumab plus docetaxel did not improve progression-free survival or overall survival versus placebo plus docetaxel in patients with ARPI-pretreated, chemotherapy-naive mCRPC. These findings do not support the use of combinations of anti-PD-1 immune checkpoint inhibitors and docetaxel in the treatment of unselected populations of patients with ARPI-pretreated, chemotherapy-naive mCRPC. FUNDING: Bristol Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Saad F, Alonso-Gordoa T, et al. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2026. PMID: 41449150. doi:10.1016/S1470-2045(25)00566-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。